SG Americas Securities LLC Buys 11,066 Shares of LivaNova PLC $LIVN

SG Americas Securities LLC raised its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 83.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,257 shares of the company’s stock after buying an additional 11,066 shares during the quarter. SG Americas Securities LLC’s holdings in LivaNova were worth $1,493,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Millennium Management LLC boosted its stake in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after acquiring an additional 544,033 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after purchasing an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP raised its holdings in LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after purchasing an additional 1,067,349 shares during the period. AQR Capital Management LLC raised its holdings in LivaNova by 30.5% in the second quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after purchasing an additional 478,525 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of LivaNova by 6.6% during the third quarter. Dimensional Fund Advisors LP now owns 1,721,173 shares of the company’s stock worth $90,154,000 after purchasing an additional 106,889 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Trading Down 0.5%

LIVN opened at $63.50 on Tuesday. The stock has a market capitalization of $3.47 billion, a P/E ratio of -14.24 and a beta of 0.97. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $71.92. The firm’s fifty day simple moving average is $64.93 and its 200 day simple moving average is $60.50.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.06. The firm had revenue of $360.92 million for the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter last year, the business posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, research analysts anticipate that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a report on Friday, March 27th. Needham & Company LLC boosted their target price on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Stifel Nicolaus set a $80.00 price target on LivaNova in a report on Wednesday, February 25th. Robert W. Baird set a $75.00 price target on LivaNova in a research report on Tuesday, December 16th. Finally, Mizuho lifted their price objective on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $74.78.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.